Benzinga Strategies
Rodman and Renshaw's Benjamin on the DNDN earnings debacle
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:14:07
- Mas informaciones
Informações:
Sinopsis
Rodman and Renshaw senior biotech analyst Dr. Reni Benjamin discusses the causes behind the more than 60% wipeout in Dendreon's market value after their earnings report and how he is tweaking his models going forward.
